Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells

Journal of Pharmacological Sciences

Volumn 116, Issue 1, 2011, Pages 107-115

  Maejima, Takashi ^a   Sugano, Tomohiro ^a   Yamazaki, Hiroyuki ^a   Yoshinaka, Yasunobu ^a   Doi, Takeshi ^a   Tanabe, Sohei ^a   Nishimaki Mogami, Tomoko ^b  

^a KOWA COMPANY LTD   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

ATP binding cassette transporter A1 (ABCA1); McARH7777; Peroxisome proliferator activated receptor (PPAR ); Pitavastatin; Sterol regulatory element binding protein (SREBP2)

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; CARNITINE PALMITOYLTRANSFERASE I; LIVER X RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL CELL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; HEPATOMA CELL; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RAT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 79956217270     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10241FP     Document Type: Article

References (31)

1. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2006;26:20-27. (Pubitemid 43732224)
2. Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care. 2009;32:S237-S245.
3. Brewer HB Jr. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:387-391.
4. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis. 2010;211:361-370.
5. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-1062.
6. Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol. 2006;21:345-352. (Pubitemid 44315068)
7. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-351. (Pubitemid 29369524)
8. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, et al. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet. 2000;24:192-196. (Pubitemid 30094724)
9. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci U S A. 2000;97:4245-4250. (Pubitemid 30226118)
10. Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, et al. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation. 2006;114:1301-1309. (Pubitemid 44402056)
11. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-438.
12. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann Pharmacother. 2010;44:507-514.
13. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138-144.
14. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res. 2010; 51:1546-1553.
15. Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb. 2009;16:654-661.
16. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004;324:835-839. (Pubitemid 39345591)
17. Sone H, Shimano H, Shu M, Nakakuki M, Takahashi A, Sakai M, et al. Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun. 2004;316:790-794. (Pubitemid 38368021)
18. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis. 2008;197:57-63. (Pubitemid 351273273)
19. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, et al. Sterol regulatory element-binding protein- 2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem. 2007;282:21090-21099. (Pubitemid 47099939)
20. Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol. 2008;51:388-395. (Pubitemid 351572238)
21. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest. 2001;107:1423-1432. (Pubitemid 32522036)
22. Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol. 2008;51:258-266. (Pubitemid 351450604)
23. Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009;205:413-419.
24. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-1342. (Pubitemid 40629053)
25. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171. (Pubitemid 32162909)
26. Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol. 2004;24:2365-2371. (Pubitemid 39658043)
27. Wu CA, Tsujita M, Hayashi M, Yokoyama S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem. 2004; 279:30168-30174. (Pubitemid 38937940)
28. Hozoji M, Munehira Y, Ikeda Y, Makishima M, Matsuo M, Kioka N, et al. Direct interaction of nuclear Liver X Receptor-β with ABCA1 modulates cholesterl efflux. J Biol Chem. 2008;283: 30057-30063.
29. Okuhira K, Fitzgerald ML, Tamehiro N, Ohoka N, Suzuki K, Sawada J, et al. Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. J Biol Chem. 2010;285:16369-16377.
30. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest. 2000;105:513-520. (Pubitemid 30127252)
31. Honzumi S, Shima A, Hiroshima A, Koieyama T, Ubukata N, Terasaka N. LXRalpha regulates human CETP expression in vitro and in transgenic mice. Atherosclerosis. 2010;212:139-145.